Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

NCT07023965 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

542

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Disease(PAD)
Arterial Occlusive Disease
Arteriosclerosis Obliterans
Thromboangiitis Obliterans
Diabetic Foot Ulcer (DFU)
Diabetic Foot Ulcer Ischemic
Critical Limb Ischemia (CLI)

Interventions

DRUG: NL003
DRUG: Placebo

Sponsor

Beijing Northland Biotech. Co., Ltd.